Measuring quality of life in patients with melanoma: Development of the FACT-Melanoma subscale

Janice N. Cormier*, Latunya Davidson, Yan Xing, Kimberly Webster, David Cella

*Corresponding author for this work

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

A systematic review of the literature on quality of life (QOL) in melanoma patients suggested an overwhelming need for a disease-specific subscale. A melanoma subscale for the Functional Assessment of Cancer Therapy (FACT-Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify questions of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients and that were to be included in a pilot questionnaire. In stage III, the pilot questionnaire and a semistructured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank, after items were reviewed and evaluated, 25 questions were retained. Most patients considered the content of the pilot questionnaire to be relevant (95%), comprehensive (60%), and easy to understand (88%). After final revisions were made, the FACT-Melanoma tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being.The face and content validity of the FACT-Melanoma assessment tool has been confirmed in melanoma patients and by professionals. Formal validation and reliability testing of the questionnaire is being determined in a prospective cohort of melanoma patients.

Original languageEnglish (US)
Pages (from-to)139-145
Number of pages7
JournalJournal of Supportive Oncology
Volume3
Issue number2
StatePublished - Mar 1 2005

Fingerprint

Melanoma
Quality of Life
Chronic Disease
Reproducibility of Results
Neoplasms
Therapeutics
Interviews
Surveys and Questionnaires

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{4a18f605846c4902b5532ba11ca28c2c,
title = "Measuring quality of life in patients with melanoma: Development of the FACT-Melanoma subscale",
abstract = "A systematic review of the literature on quality of life (QOL) in melanoma patients suggested an overwhelming need for a disease-specific subscale. A melanoma subscale for the Functional Assessment of Cancer Therapy (FACT-Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify questions of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients and that were to be included in a pilot questionnaire. In stage III, the pilot questionnaire and a semistructured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank, after items were reviewed and evaluated, 25 questions were retained. Most patients considered the content of the pilot questionnaire to be relevant (95{\%}), comprehensive (60{\%}), and easy to understand (88{\%}). After final revisions were made, the FACT-Melanoma tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being.The face and content validity of the FACT-Melanoma assessment tool has been confirmed in melanoma patients and by professionals. Formal validation and reliability testing of the questionnaire is being determined in a prospective cohort of melanoma patients.",
author = "Cormier, {Janice N.} and Latunya Davidson and Yan Xing and Kimberly Webster and David Cella",
year = "2005",
month = "3",
day = "1",
language = "English (US)",
volume = "3",
pages = "139--145",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "2",

}

Measuring quality of life in patients with melanoma : Development of the FACT-Melanoma subscale. / Cormier, Janice N.; Davidson, Latunya; Xing, Yan; Webster, Kimberly; Cella, David.

In: Journal of Supportive Oncology, Vol. 3, No. 2, 01.03.2005, p. 139-145.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Measuring quality of life in patients with melanoma

T2 - Development of the FACT-Melanoma subscale

AU - Cormier, Janice N.

AU - Davidson, Latunya

AU - Xing, Yan

AU - Webster, Kimberly

AU - Cella, David

PY - 2005/3/1

Y1 - 2005/3/1

N2 - A systematic review of the literature on quality of life (QOL) in melanoma patients suggested an overwhelming need for a disease-specific subscale. A melanoma subscale for the Functional Assessment of Cancer Therapy (FACT-Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify questions of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients and that were to be included in a pilot questionnaire. In stage III, the pilot questionnaire and a semistructured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank, after items were reviewed and evaluated, 25 questions were retained. Most patients considered the content of the pilot questionnaire to be relevant (95%), comprehensive (60%), and easy to understand (88%). After final revisions were made, the FACT-Melanoma tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being.The face and content validity of the FACT-Melanoma assessment tool has been confirmed in melanoma patients and by professionals. Formal validation and reliability testing of the questionnaire is being determined in a prospective cohort of melanoma patients.

AB - A systematic review of the literature on quality of life (QOL) in melanoma patients suggested an overwhelming need for a disease-specific subscale. A melanoma subscale for the Functional Assessment of Cancer Therapy (FACT-Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify questions of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients and that were to be included in a pilot questionnaire. In stage III, the pilot questionnaire and a semistructured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank, after items were reviewed and evaluated, 25 questions were retained. Most patients considered the content of the pilot questionnaire to be relevant (95%), comprehensive (60%), and easy to understand (88%). After final revisions were made, the FACT-Melanoma tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being.The face and content validity of the FACT-Melanoma assessment tool has been confirmed in melanoma patients and by professionals. Formal validation and reliability testing of the questionnaire is being determined in a prospective cohort of melanoma patients.

UR - http://www.scopus.com/inward/record.url?scp=15944426057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944426057&partnerID=8YFLogxK

M3 - Review article

C2 - 15796446

AN - SCOPUS:15944426057

VL - 3

SP - 139

EP - 145

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 2

ER -